A growing wave of legal action targets GLP-1 receptor agonist manufacturers, with over 90 plaintiffs claiming the popular diabetes and weight management medications triggered vision complications. These cases highlight emerging concerns about ocular side effects in patients using drugs like semaglutide and tirzepatide. Legal experts suggest the lawsuits aim to establish potential links between these widely prescribed pharmaceuticals and rare eye disorders. The litigation underscores the importance of comprehensive safety monitoring as these medications gain mainstream adoption for metabolic health management.

Summary auto-generated by AI from the original publisher's content. Editorial standards.